The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

Mural Oncology (MURA) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s (MRK) anti-PD-1 therapy, ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...